DLBCL in Focus: Transforming Outcomes With CAR T Therapy

March 3, 2025

By Krish Patel, MD
Saurabh Dahiya, MD, FACP

Opinion

Video

Panelists discuss how the diffuse large B-cell lymphoma (DLBCL) treatment landscape has seen significant evolution with the integration of targeted therapies and chimeric antigen receptor T-cell treatments, supplementing traditional R-CHOP. However, early relapsed/refractory cases remain challenging due to complex tumor biology and resistance mechanisms. This underscores the need for better up-front risk stratification tools and biomarker-driven treatment selection.

Now Viewing

EP: 1.DLBCL in Focus: Transforming Outcomes With CAR T Therapy

EP: 2.Beyond Salvage: When to Move to CAR T in Relapsed DLBCL

EP: 3.Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL

EP: 4.TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL

EP: 5.CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management

EP: 6.Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection

EP: 7.Personalizing CAR T: Making the Right Call for Each Patient

EP: 8.Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL

EP: 9.Transplant-Eligible, CAR T Considered: How Do We Decide?

EP: 10.CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease

EP: 11.The Future of DLBCL: Innovations in Therapy and Patient Care

Video content above is prompted by the following:

How has the treatment landscape for DLBCL evolved recently, and what have been the most impactful advancements?
Despite advances in frontline therapy, why do we still see poor outcomes in early relapsed/refractory patients, and how should this inform our approach to risk stratification?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!